These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 18495330)

  • 1. Induction of long-lasting antitumor immunity by concomitant cell therapy with allogeneic lymphocytes and trifunctional bispecific antibody.
    Morecki S; Lindhofer H; Yacovlev E; Gelfand Y; Ruf P; Slavin S
    Exp Hematol; 2008 Aug; 36(8):997-1003. PubMed ID: 18495330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of trifunctional bispecific antibodies to prevent graft versus host disease induced by allogeneic lymphocytes.
    Morecki S; Lindhofer H; Yacovlev E; Gelfand Y; Slavin S
    Blood; 2006 Feb; 107(4):1564-9. PubMed ID: 16234351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogeneic versus syngeneic killer splenocytes as effector cells for the induction of graft-versus-tumor effect.
    Morecki S; Yacovlev E; Gelfand Y; Vilensky A; Slavin S
    Biol Blood Marrow Transplant; 2004 Jan; 10(1):40-8. PubMed ID: 14752778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic cell-mediated immunotherapy for eradication of minimal residual disease: comparison of T-cell and IL-2 activated killer (LAK) cell-mediated adoptive immunotherapy in murine models.
    Vourka-Karussis U; Ackerstein A; Pugatsch T; Slavin S
    Exp Hematol; 1999 Mar; 27(3):461-9. PubMed ID: 10089908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity of an EpCAM/CD3-bispecific BiTE antibody during long-term treatment of mice in the absence of T-cell anergy and sustained cytokine release.
    Amann M; D'Argouges S; Lorenczewski G; Brischwein K; Kischel R; Lutterbuese R; Mangold S; Rau D; Volkland J; Pflanz S; Raum T; Münz M; Kufer P; Schlereth B; Baeuerle PA; Friedrich M
    J Immunother; 2009 Jun; 32(5):452-64. PubMed ID: 19609237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opsonization with a trifunctional bispecific (alphaCD3 x alphaEpCAM) antibody results in efficient lysis in vitro and in vivo of EpCAM positive tumor cells by cytotoxic T lymphocytes.
    Schmitt M; Schmitt A; Reinhardt P; Thess B; Manfras B; Lindhofer H; Riechelmann H; Wiesneth M; Gronau S
    Int J Oncol; 2004 Oct; 25(4):841-8. PubMed ID: 15375531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent inhibition of local and disseminated tumor growth in immunocompetent mouse models by a bispecific antibody construct specific for Murine CD3.
    Schlereth B; Kleindienst P; Fichtner I; Lorenczewski G; Brischwein K; Lippold S; da Silva A; Locher M; Kischel R; Lutterbüse R; Kufer P; Baeuerle PA
    Cancer Immunol Immunother; 2006 Jul; 55(7):785-96. PubMed ID: 16187083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New gene-immunotherapy combining TRAIL-lymphocytes and EpCAMxCD3 Bispecific antibody for tumor targeting.
    Groth A; Salnikov AV; Ottinger S; Gladkich J; Liu L; Kallifatidis G; Salnikova O; Ryschich E; Giese N; Giese T; Momburg F; Büchler MW; Moldenhauer G; Herr I
    Clin Cancer Res; 2012 Feb; 18(4):1028-38. PubMed ID: 22228630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct.
    Schlereth B; Fichtner I; Lorenczewski G; Kleindienst P; Brischwein K; da Silva A; Kufer P; Lutterbuese R; Junghahn I; Kasimir-Bauer S; Wimberger P; Kimmig R; Baeuerle PA
    Cancer Res; 2005 Apr; 65(7):2882-9. PubMed ID: 15805290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 1. Alloimmune-mediated graft-versus-leukemia (GVL) effects induced by unmodified and in vitro rIL-2-activated bone marrow and lymphocytes from different lymphoid compartments.
    Weiss L; Reich S; Slavin S
    Cytokines Cell Mol Ther; 1999 Sep; 5(3):145-52. PubMed ID: 10641572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trifunctional bispecific antibodies induce tumor-specific T cells and elicit a vaccination effect.
    Eissler N; Ruf P; Mysliwietz J; Lindhofer H; Mocikat R
    Cancer Res; 2012 Aug; 72(16):3958-66. PubMed ID: 22745368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel approach for prevention of lethal GVHD by selective elimination of alloreactive donor lymphocytes prior to stem cell transplantation.
    Panigrahi S; Morecki S; Yacovlev E; Gelfand Y; Kassir J; Slavin S
    Exp Hematol; 2004 Aug; 32(8):756-64. PubMed ID: 15308327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial.
    Buhmann R; Michael S; Juergen H; Horst L; Peschel C; Kolb HJ
    J Transl Med; 2013 Jul; 11():160. PubMed ID: 23815981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAM x alpha CD3).
    Riesenberg R; Buchner A; Pohla H; Lindhofer H
    J Histochem Cytochem; 2001 Jul; 49(7):911-7. PubMed ID: 11410615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic window of MuS110, a single-chain antibody construct bispecific for murine EpCAM and murine CD3.
    Amann M; Brischwein K; Lutterbuese P; Parr L; Petersen L; Lorenczewski G; Krinner E; Bruckmeier S; Lippold S; Kischel R; Lutterbuese R; Kufer P; Baeuerle PA; Schlereth B
    Cancer Res; 2008 Jan; 68(1):143-51. PubMed ID: 18172306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
    Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
    J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody.
    Ruf P; Lindhofer H
    Blood; 2001 Oct; 98(8):2526-34. PubMed ID: 11588051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-growth inhibition with bispecific antibody fragments in a syngeneic mouse melanoma model: the role of targeted T-cell co-stimulation via CD28.
    Grosse-Hovest L; Brandl M; Dohlsten M; Kalland T; Wilmanns W; Jung G
    Int J Cancer; 1999 Jan; 80(1):138-44. PubMed ID: 9935244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of graft-versus-leukemia (GVL) effect without graft-versus-host disease (GVHD) by pretransplant donor treatment with immunomodulators.
    Morecki S; Yacovlev E; Gelfand Y; Shabat Y; Slavin S
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):406-15. PubMed ID: 19285627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pretransplant treatment of donors with immunomodulators to control graft-versus-host disease (GVHD) in transplant recipients.
    Morecki S; Yacovlev E; Gelfand Y; Eizik O; Slavin S
    Exp Hematol; 2007 May; 35(5):748-56. PubMed ID: 17577924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.